Amgen to acquire Nuevolution in million-dollar deal
US drug group Amgen has offered to acquire its Danish partner Nuevolution for USD 167 million - an increase by 169 percent relative to Nuevolution's closing price Tuesday this week. The board recommends that the shareholders accept the offer.
US drug group Amgen is about to acquire Danish biotech firm Nuevolution.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
